Table 1

Univariable Cox proportional hazards regression analysis for risk factor association with death (all-cause mortality) in dogs diagnosed with hyperadrenocorticism at primary care veterinary practices in England (n=219)

VariableFrequency (%)Median survival time (days)95% CIHR95% CICategory P value*Variable P value†
Weight (kg)0.002
 <15135 (61.6)634424 to 726Baseline--
 ≥1584 (38.4)427296 to 5301.611.19 to 2.180.002
Age at diagnosis (years)
 <1074 (33.8)718593 to 896Baseline--<0.001
 10 to <1396 (43.8)458319 to 6371.481.04 to 2.120.029
 ≥1349 (22.4)239144 to 4492.941.93 to 4.48<0.001
Sex neuter
 Female entire18 (8.2)427178 to 12231.040.56 to 1.920.9110.899
 Female neutered86 (39.3)442355 to 637Baseline--
 Male entire32 (14.6)535159 to 7141.130.73 to 1.760.578
 Male neutered83 (37.9)546376 to 7180.950.68 to 1.330.780
Sex
 Female104 (47.5)440355 to 637Baseline--0.970
 Male115 (52.5)535376 to 6830.990.74 to 1.340.970
Neuter status
 Entire50 (22.8)535220 to 714Baseline--
 Neutered169 (77.2)510412 to 6181.130.79 to 1.610.5010.506
Insured
 Yes126 (57.5)517412 to 6420.740.52 to 1.070.1130.059
 No52 (23.7)332219 to 535Baseline--
 Unrecorded41 (18.8)717442 to 8960.550.34 to 0.910.018
Breed
 Crossbred47 (21.5)432221 to 726Baseline--0.286
 Bichon Frise13 (5.9)540119 to 12590.720.36 to 1.450.361
 Jack Russell terrier21 (9.6)807484 to 14450.570.31 to 1.040.065
 Staffordshire bull terrier13 (5.9)700215 to 9411.010.54 to 1.890.977
 West Highland white terrier12 (5.5)39672 to 10220.930.46 to 1.850.832
 Yorkshire terrier16 (7.3)642239 to 10150.800.43 to 1.500.487
 Other purebreds97 (44.3)440311 to 5681.100.75 to 1.620.618
Purebred status
 Purebred172 (78.5)532424 to 637Baseline--0.637
 Crossbred47 (21.5)432221 to 7261.090.77 to 1.550.635
Weight to breed
 Average81 (37.0)479332 to 681Baseline--0.900
 Above73 (33.3)596441 to 7170.930.65 to 1.330.705
 Below20 (9.1)373199 to 7391.090.61 to 1.950.769
 Crossbreed45 (20.6)389217 to 7261.070.72 to 1.600.728
Treated with trilostane
 Yes206 (94.1)521416 to 634Baseline--0.600
 No13 (5.9)1783 to 10151.200.61 to 2.360.590
Trilostane dose frequency
 Once daily178 (81.3)532424 to 634Baseline--0.372
 Twice daily16 (7.3)833311 to 11090.710.41 to 1.230.226
 Not given13 (5.9)1783 to 10151.200.61 to 2.360.584
 Unknown12 (5.5)
Mean lifetime trilostane dose (mg/kg)
 Not given13 (5.9)1783 to 1015
 ≤368 (31.1)449308 to 6051.160.78 to 1.740.4620.463
 >3131 (59.8)596427 to 718Baseline--
 Missing7 (3.2)
Comorbidities
Neurological signs
 Yes45 (20.6)479300 to 5961.441.01 to 2.030.0420.048
 No174 (79.5)535389 to 689Baseline--
Hypertensive
 Yes27 (12.3)660429 to 779Baseline--0.881
 No15 (6.9)479178 to 7530.930.46 to 1.840.826
 Not checked177 (80.8)479357 to 6050.870.48 to 1.580.650
Diabetes mellitus
 Yes22 (10.1)479119 to 11020.910.57 to 1.460.6980.695
 No197 (89.9)510412 to 605Baseline--
No. of comorbidities
 078 (35.6)334225 to 432Baseline--
 ≥1141 (64.4)568479 to 7151.230.89 to 1.700.1980.210
Changes to trilostane
 Increased55 (25.1)733532 to 9410.500.34 to 0.73<0.0010.002
 Decreased23 (10.5)681308 to 8300.560.34 to 0.930.023
 No change94 (42.9)332221 to 432Baseline--
 Stopped34 (15.6)546412 to 7170.730.48 to 1.100.133
 Not given13 (5.9)
Pre-ACTH cortisol (nmol/l)
 Unknown154 (70.3)449355 to 6051.440.95 to 2.190.0890.154
 <15034 (15.5)577340 to 942Baseline--
 ≥15031 (14.2)52184 to 8311.580.93 to 2.700.092
Post-ACTH cortisol (nmol/l)
 Unknown142 (64.8)449334 to 6181.480.98 to 2.230.0620.091
 <80036 (16.5)779577 to 1041Baseline--
 ≥80041 (18.7)432269 to 5351.641.00 to 2.680.049
  • *Wald P value.

  • †LRT P value.

  • ACTH, adrenocorticotropic hormone; LRT, likelihood ratio test.